Last summer, we published a notice of information on our priorities for sepsis research that applies to all active NIGMS funding opportunity announcements. We’ve now published a notice of special interest (NOT-GM 20-028) to promote early-stage research and development projects through the NIH SBIR/STTR program.
We’re interested in receiving applications from small businesses or from small businesses and their academic partners that propose to develop novel tools and technologies for sepsis research, detection, and treatment. We’re specifically interested in diagnostic tools, predictive clinical algorithms, and technologies to facilitate molecular phenotyping of sepsis patients.
If you have any questions about NIGMS priorities for small business development of sepsis diagnostics and therapeutics, please contact me.
Because many people in the research community are facing considerable challenges trying to juggle various responsibilities during the COVID-19 outbreak, NIGMS will accommodate late application submissions for due dates in May 2020 for all NIGMS-specific FOAs (see NOT-GM-20-029). For applications submitted through June 30, 2020, institutions do not need to request advance permission or provide a cover letter to justify a late submission to these FOAs. Applications with due dates prior to May 25 should use FORMS E and those with due dates on or after May 25 should use FORMS F, regardless of the date of submission.
Continue reading “Policy on Late Submissions of NIGMS Applications Due in May 2020”
Ninety percent of the applications to our Maximizing Investigators’ Research Award for Early Stage Investigators (known as the ESI MIRA program) that were submitted in October are about to undergo peer review. The remaining 10% were administratively withdrawn, mostly because the research proposed fell outside the NIGMS mission. This is comparable to the proportion that was withdrawn over the past 3 years.
Withdrawn applications represent a lot of wasted time and effort on the part of affected PIs and are the source of considerable frustration. So what can you do to minimize the chance of this happening to your ESI MIRA application in the future?
Continue reading “How do I know if my work fits in the mission of NIGMS?”
At the September meeting of the NIGMS Advisory Council, I delivered the Institute’s response to the recommendations of the Working Group on Sepsis. For more information, you can watch the videocast of the presentation.
Continue reading “Advancing Sepsis Research: New Models and Novel Approaches”
We’ve issued a funding opportunity announcement (FOA) PAR-19-367
to maintain continued support of our Maximizing
Investigators’ Research Award (MIRA) program. Under this new FOA,
investigators with an active NIGMS R35 grant (both early-stage and established
investigator MIRA) can submit renewal MIRA applications, and investigators with
a single-PI R01-equivalent NIGMS award (DP1, DP2, R01, R37, SC1) can submit new
Continue reading “NIGMS Continues Its MIRA Program”
Prospective applicants frequently ask us whether their application ideas fit within our mission. NIGMS supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. We also support research in some specific clinical areas that affect multiple organ systems, including anesthesia, sepsis, wound healing, and trauma. In addition, we’re committed to training the next generation of scientists, enhancing the diversity of the scientific workforce, and developing research capacity throughout the country.
Not all applications for fundamental biomedical research projects will ultimately be assigned to NIGMS. Other NIH institutes and centers (ICs) also have strong commitments to basic research that underlie an understanding of their own particular organ systems, diseases, or treatments. Each NIH IC is different and supports distinct research areas, so it’s wise to seek advice from the program where your science best fits. Before submitting an application to NIGMS, we strongly recommend that you contact the program director whose portfolio most closely matches your area of research.
Continue reading “Does your application fit the scientific mission of NIGMS?”
For the past few months, NIGMS has been reviewing its HIV/AIDS grant portfolio. As the HIV/AIDS field has matured and the necessary research directions have become clearer, the HIV/AIDS-related grants we’ve supported have, appropriately, become more narrowly focused. Because of this, and after close consultation with leadership at the National Institute of Allergy and Infectious Diseases (NIAID), we’ve concluded that it’s in the best interest of the research to transition NIGMS’ HIV/AIDS portfolio to NIAID to allow improved scientific coordination, prioritization, and efficiency of management.
Continue reading “NIGMS-Managed HIV/AIDS Research Transitioning to NIAID”
UPDATE: If you are looking for the program director of a specific NIGMS research portfolio, please see our Contacts by Research Area page.
Like most organizations, NIGMS has been modernizing many of its systems. One recent change is our phone system. To increase efficiency and to enable our support staff to handle higher-level responsibilities, we want you to know that the best way to now reach a program director or scientific review administrator is to send him or her an email. If you want the person to call you back, please provide your contact information and grant or application number. If you don’t know the email address of the NIGMS staff member, it can be found easily by entering the name in our Staff Directory. This directory also provides direct phone numbers of each staff member where you can leave a voicemail message.
The NIGMS website provides information that you may find helpful in determining the staff member you want to contact. If you are still uncertain about whom to contact, you may call the main NIGMS phone number (301-496-7301) and leave a message.
NIGMS’ program staff are, as always, interested in hearing from you, answering your questions, and addressing your concerns.